Product Images Gemcitabine Hydrochloride

This appears to be a comparison of median progression-free survival times between two treatments for a particular type of cancer. Gemcitabine/Carboplatin had a median progression-free survival of 8.6 months, while Zos Carboplatin had a median progression-free survival of 58 months. The log rank is calculated to be 0.0038, suggesting a significant difference in progression-free survival between the two treatments. There also appears to be a graph showing the percentage of patients with progression-free survival plotted against the number of months, with two lines representing the two treatments being compared.*

The text describes the results of a study comparing two treatments for a certain disease. The study measured the median time to documented disease progression for two treatments - GemcitabinePaclitaxel and Paclitaxel. The results show that the median time to disease progression with GemcitabinePaclitaxel was 5.2 months, while with Paclitaxel it was only 2.9 months. The study found the difference between the two treatments to be significant, with a log rank p-value of <0.0001. There is additional information in the text, including the treatment groups and some numbers that are hard to read due to the .*

This text provides information on the survival probabilities and median survival rates of two different treatments for an unknown condition. The treatments are referred to as Gem/Cis and Cis. The table shows the survival probability and survival time in months with the respective treatments. The statistical significance of each treatment is evaluated using the Logrank and Wilcoxon tests.*

This appears to be a graph displaying the "Fraction Surviving" for two different treatments (5-FU and Gemcitabine) over a period of 16 months, with time (in months) on the x-axis and the percentage of patients surviving on the y-axis. The graph shows a decreasing trend in survival over time for both treatments. However, without further context or information, it is difficult to interpret the specific results of the study.*

Gemcitabine for Injection, USP is a medication that comes in a single-use 200mg vial. The vial should not be refrigerated beforehand and is intended for intravenous use only. The medication should be used carefully and only in an approved medical setting under the supervision of a medical professional. It is unclear what the areas for serial number, expiry, and batch number are, but it seems they will be printed later in the commercial packing process. The manufacturer of the medication is Cipla.*

This is a description of the product labeling process for batch overprinting. The text shows a product's GTIN, serial number, expiry, and lot will be printed during commercial packing. The product is Gemcitabine for Injection, USP, and it is for intravenous use only. The vial is sterile and is a single dose. The text mentions not to refrigerate the product. The manufacturer is Cipla. There are also some unreadable characters indicated as yophized and yophitzsa.*